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Edited by Ned ManteiAbstract Alternative splicing has an important role in the tis-
sue-speciﬁc regulation of gene expression. Here we report that
similar to the human NPFF2 receptor, the mouse NPFF2 recep-
tor is alternatively spliced. In human the presence of three alter-
natively spliced receptor variants were veriﬁed, whereas two
NPFF2 receptor variants were identiﬁed in mouse. The alterna-
tive splicing aﬀected the 5 0 untranslated region of the mouse
receptor and the variants in mouse were diﬀerently distributed.
The mouse NPFF system may also have species-speciﬁc features
since the NPFF2 receptor mRNA expression diﬀers from that re-
ported for rat.
 2006 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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Neuropeptide1. Introduction
Neuropeptide FF (NPFF) was discovered 20 years ago [1]
and it appears to participate in several physiological functions
both in the CNS and non-neuronal tissues. In accordance with
its known functions in pain transmission and endocrine func-
tions, NPFF is found in the posterior pituitary, dorsal horn
of the spinal cord, the hypothalamus and pons-medulla [2–
4]. Besides the distinct distribution in the central nervous sys-
tem (CNS), NPFF is found in the periphery [5], and it is se-
creted into blood [6].
The target molecules for NPFF and related peptides,
NPFF1 and NPFF2 receptors, were identiﬁed recently [7–
10]. The expression patterns of the two NPFF receptors are
distinct [7,11], suggesting functional diﬀerences between them.
In neuroblastoma cells NPFF signals through endogenous
NPFF2 receptor [12] and currently, it seems that NPFF2
receptor is the receptor mostly responsible for the eﬀects ofAbbreviations: 50RACE, rapid ampliﬁcation of cDNA 50 ends; 50UTR,
5 0untranslated region; GAPDH, glyceraldehyde-3-phosphate dehydro-
genase; NPFF, neuropeptide FF; PBGD, phorphobilinogen deaminase
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receptor [13,14], but a ligand was found soon after the initial
discovery ([7,8]; Table S1). Interestingly, the reported NPFF2
receptor sequences are not identical and might represent alter-
native splice variants of the receptor. The gene for the mouse
NPFF2 receptor has been cloned [11,14], but its mRNA distri-
bution has not been described and the mouse NPFF2 receptor
splice variants are unknown.
In this study, we show that human and mouse NPFF2 recep-
tors are alternatively spliced. We cloned and analyzed the
splice variants and investigated the tissue-speciﬁc expression
of mouse NPFF2 receptor transcripts.2. Materials and methods
2.1. Experimental animals
The permission for the mouse experiments was obtained from the
Institutional Animal Care and Use committee of Abo Akademi Uni-
versity. All the experiments were conducted in accordance with the
European community council directive 68/609/EEC guidelines. Adult
male mice (C57B6/6ola or ICR wild type mice) were maintained at a
12-h dark–light cycle with food and water available ad libitum. The
animals (n = 3) were sacriﬁced by the administration of CO2 followed
by decapitation. The brains were dissected and frozen in isopentane.
The frozen tissues were embedded in Embedding MatrixR (Shandon,
Pittsburg, PA, USA) and sectioned at 20 C. Twenty micrometer sec-
tions were thaw-mounted on poly-L-lysine slides (Menzel-Gla¨ser,
Braunschweig, Germany). For the RNA isolation the tissues were fro-
zen in liquid nitrogen. The human placenta tissue sample was obtained
from the Turku University Hospital (Turku, Finland) with the permis-
sion of the patient.
2.2. RNA isolation and cDNA synthesis
Total RNA from human placenta and mouse tissues was isolated
with RNAwiz protocol (Ambion Inc., Austin, TX, USA). The total
RNA was treated with DNaseI (Promega, Maddison, WI, USA) be-
fore the cDNA synthesis. cDNA from total RNA was produced with
Superscript First-Strand Synthesis System for RT-PCR (Invitrogen,
Carlsbad, CA, USA).
2.2.1. Rapid ampliﬁcation of cDNA 5 0 ends (5 0 RACE). Five micro-
grams of human placental or mouse brain total RNA was used as tem-
plate material for the GeneRacer kit (Invitrogen). A primary and
nested PCR was performed with RNA-oligonucleotide speciﬁc for-
ward primers provided by the kit and gene-speciﬁc reverse primers
(Table S2). The PCR products were cloned into pGEM-T Easy vector
(Promega) and several recombinant clones were isolated for sequenc-
ing analysis.
2.2.2. RT-PCR analysis of the expression of mouse NPFF2 recep-
tor. Two sets of mouse NPFF2 receptor speciﬁc primers extending
over introns were used for the RT-PCR analysis of the mouse NPFF2
receptor transcripts in non-neuronal tissues and diﬀerent brain areas
(Table S2). The samples were also analyzed for the expression ofblished by Elsevier B.V. All rights reserved.
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non-neuronal tissue samples and phorphobilinogen deaminase
(PBGD) in the case of CNS samples. The samples were analyzed with
agarose gel electrophoresis using ethidium bromide to visualize the
PCR products.2.3. In situ hybridization
The probes (Table S2) were 3 0 end labeled with [33P]- or [35S]-deoxy-
adenosine 5-(-thio) triphosphate (AmershamBiosciences, Buckingham-
shire, UK) using terminal deoxynucleotide transferase (Promega). The
hybridization procedure has been described in detail before [5]. A 100-
fold excess of unlabeled speciﬁc probe was used to inhibit binding of the
labeled probe in control samples. The sections were exposed to Kodak
BioMax X-ray ﬁlms (Eastman Kodak, Rochester, NY, USA).3. Results and discussion
3.1. The splice variants of human NPFF2 receptor
Since its initial discovery, several sequences for the human
NPFF2 receptor have been published (Table S1). Apparently,
these diﬀerent NPFF2 receptor sequences represent alternative
splice variants. First, we conﬁrmed the identity of the human
NPFF2 transcripts. After analyzing a number 5 0RACE clones,
three distinct receptor variants were veriﬁed (Fig. 1A and B).
The shortest transcript, NPFF2 receptor variant1, corre-
sponded to the GenBank AF257210 sequence. The variant2
diﬀered from the variant1 at its 5 0untranslated region (5 0UTR)
and it had a putative alternative start codon nine nucleotides
upstream of the reported start codon. The variant2 corre-
sponded to AF236083. The NPFF2 receptor variant3 had a
long N-terminal extension that was not found in the other vari-
ants, and corresponded to AF119815. The exon–intron struc-
tures of the variants are shown in Fig. 1A and the exon–
intron junctions in detail in Fig. 1B.
Of the three cloned NPFF2 receptor variants only the vari-
ant3 diﬀers signiﬁcantly in protein coding sequence. Laemmle
et al. [15] showed that this isoform has much lower aﬃnity to
NPFF peptides than NPFF2 receptor. Thus, in human the
NPFF2 receptor variant3 may have a distinct function from
the other variants. Laemmle et al. [15] detected yet another
NPFF2 receptor variant that is lacking exons1–3 and repre-
sents a truncated receptor. This truncated transcript was not
detected by the primers used in this study. The exon2 found
in the variant2 contains an alternative start codon. Whether
this start codon upstream of the reported transcription start
site is actually used, remains to be studied.3.2. The splice variants of mouse NPFF2 receptor
Since mouse is an extensively used species to study the
NPFF system, we next asked whether the mouse NPFF2
receptor is alternatively spliced. The 5 0RACE analysis of
mouse whole brain RNA revealed two NPFF2 receptor tran-
scripts in mouse (Fig. 1A and C). The coding regions, but
not the 5 0UTRs, of the cloned mouse NPFF2 receptor splice
variants corresponded to GenBank NM_133192. The 5 0UTR
reported for NM_133192 was not detected by 5 0RACE or tra-
ditional cloning. The BLAST search for this sequence showed
it to be a repetitive sequence and maybe a cloning artefact.
Similar to human, the mouse NPFF2 receptor variants diﬀered
only slightly in their coding sequence but the additional exon
in variant2 introduced a 5 0UTR that is missing in the variant1.
The mouse variant2 had a putative alternative start codon butit was followed by a termination codon and, thus, the protein
coding sequence of the two mouse NPFF2 receptor variants
appears to be the same. The strength of the putative splice sites
was analyzed with Alternative Splice Site Predictor [16]. The
exon1a and exon2 were found in both mouse variants and in
accordance with this, donor splice site of the exon1a and the
acceptor and donor sites of the exon2 showed very high scores
for constitutive splice sites. The exon1b was found only in the
receptor variant2 and it had splice site sequences typical for
alternative splicing. In spite of the cloning eﬀorts, a human
variant3-like transcript was not detected in mouse. Accord-
ingly, alternative splicing is reported to be more frequent in hu-
man than in mouse, both in terms of percentage of genes that
are alternatively spliced and the number of alternative splicing
events per gene [17]. Although the receptor variants1 and 2
hardly diﬀer in their protein coding sequence, they do have a
signiﬁcantly diﬀerent 5 0UTR sequences. At least 25% of all
alternative exons are predicted to regulate transcript abun-
dance and the alternative splicing of the 5 0UTR may have
drastic eﬀects on the gene expression [18–20]. Thereby, the
alternatively spliced 5 0UTR may have a role in the regulation
of NPFF2 receptor expression.3.3. Expression of NPFF2 receptor splice variants in mouse
Interestingly, the conserved alternative splicing did not
change the reading frame of the transcript. Such conserved
modular alternative splicing events seem to be associated with
tissue-speciﬁc regulation of splicing [21]. Therefore, the expres-
sion pattern of the mouse receptor variants was analyzed by
in situ hybridization and by RT-PCR. Furthermore, since
there are signiﬁcant diﬀerences in the NPFF binding between
species [11] and even rodent strains [22], it was considered of
importance to determine the NPFF2 receptor mRNA expres-
sion pattern in mouse. In addition, the diﬀerential expression
of the receptor variants has not been studied.
The expression of NPFF2 receptor was detected at restricted
sites in the mouse CNS (Fig. 2). The highest expression level
was detected at the external plexiform layer of the olfactory
bulb (EPl) and a strong signal in the nucleus of the solitary
tract (Sol), dorsal tegmental nucleus (DTg) and reunions tha-
lamic nucleus (Re). Moderate or low level of expression was
detected also at other sites. Mouse NPFF2 receptor variant 2
mRNA was detected only in the olfactory bulb (Fig. 3).
The individual contribution of the receptor variant1 to the
NPFF2 receptor expression could be revealed by RT-PCR.
To get a more complete view of the contribution of the tran-
scripts in mouse, the expression of the splice variants in periph-
eral organs was analyzed. Based on the RT-PCR analysis both
variants were expressed in several brain regions (Fig. 4A) and
non-neuronal tissues (Fig. 4B), but their relative abundance
varied markedly between tissues. The analysis of brain regions
with RT-PCR showed wider expression of NPFF2 receptor
than was expected based on the in situ hybridization data
(Data S1). In general, the variant2 was more abundant in
the non-neuronal tissues and whole brain. In the CNS, the var-
iant1 was more abundant than the variant2 only in the olfac-
tory bulb. Similar to in situ hybridization analysis, the RT-
PCR analysis of the CNS (Fig. 4A) indicated the highest
NPFF2 receptor mRNA expression in the olfactory bulb.
The role of NPFF in the olfactory system is not known and
should be further investigated in detail. The strong mRNA sig-
Fig. 1. Structure and sequence of the 5 0 end of the human and mouse NPFF2 receptor genes. (A) Schematic presentation of the 5 0 ends of the cloned
human and mouse NPFF2 receptor transcripts. The solid line represents human/mouse NPFF2 receptor variant1, dashed-dotted line human/mouse
NPFF2 receptor varian2 and dotted line human NPFF2 receptor variant3. (B) The genomic sequence of the 5 0 end of the human NPFF2 receptor
gene (EMBL genomic database AC106898 and AC106051, Homo sapiens chromosome 4), and (C) mouse NPFF2 receptor gene (EMBL genomic
database AC134840, Mus musculus chromosome 5). Introns at lower case and exons at upper case, the splice sites underlined and in bold face, and
putative start codons in bold.
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Fig. 2. The distribution of the NPFF2 receptor mRNA in the mouse CNS analyzed with in situ hybridization (A–H). Scale bar 0.1 mm. Arc, arcuate
hypothalamic nucleus; DTg, dorsal tegmental nucleus; En, endopiriform nucleus; EPl, external plexiform layer of olfactory bulb; ICj, islands of
Calleja; LSt, lateral striatal stripe; MPA, medial preoptic area; PAG, periaqueductal gray; PB, parabrachial nucleus; PH, posterior hypothalamic
area; PrC, precommisural nucleus; Re, reunions thalamic nucleus; Sol, nucleus of the solitary tract; SuG, superﬁcial gray, superior colliculus; Tu,
olfactory tubercle.
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tor may modulate olfactory singalling on the level of mitral or
granule cells.
The results from the RT-PCR analysis are well in accor-
dance with the in situ hybridization data. The only exception
is the hippocampus where no signal was detected with in situ
hybridization but a clear band was observed with RT-PCR.
The results are also in accordance with NPFF receptor binding
studies. The NPFF2 receptor mRNA was detected only at sites
where also receptor binding has been described [11,23]. How-
ever, the receptor binding studies have shown signals at sites
where no NPFF2 receptor mRNA was detected in this study.
As the NPFF mRNA expressing neurons do not project to
these binding sites, some other receptor(s) may contribute tosignal detected with the NPFF radioligands. The comparison
of the mouse NPFF2 receptor mRNA expression with rat
shows that there are distinct species diﬀerences. In accordance
with this, the distribution of NPFF2 receptor ligand binding
sites is diﬀerent in mouse and rat [11]. There are also diﬀer-
ences in the NPFF2 receptor mRNA expression between hu-
man and rat [7], implying that the NPFF system may have
distinct species-speciﬁc features.4. Conclusions
These data together with the previously published reports
support the ﬁnding that human and mouse NPFF2 receptors
Fig. 3. The distribution of NPFF2 receptor splice variants in the mouse CNS analyzed with in situ hybridization. Representative sites are shown. (A
and C) Probe detecting the total NPFF2 receptor; (B and D) probe speciﬁc for variant2. Scale bar 0.1 mm. EPl, external plexiform layer of olfactory
bulb; Sol, nucleus of the solitary tract.
Fig. 4. The distribution of the mouse NPFF2 receptor splice variants analyzed with RT-PCR. (A) CNS.Upper panel: NPFF2 receptor splice variants.
Lower panel: PBGD. Samples from left to right: marker (M), spinal cord (Sc), pons, medulla oblongata (Med), midbrain (MBr), hypothalamus (Hpt),
thalamus (Thal), hippocampus (Hc), cerebral cortex (Cc), cerebellum (Cb), pituitary (Pit), striatum (Str), and olfactory bulb (Ob). (B) Non-neuronal
tissues.Upper panel: NPFF2 receptor splice variants. Lower panel: GAPDH. Samples from left to right: marker (M), whole brain, liver, lung, testis,
pancreas (pancr), kidney, spleen, thymus, and adrenals.
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receptor variants compared to two found in mouse. The vari-
ants1 and 2 have a similar exon–intron structure in mouse and
human. The alternative splicing may be involved in the regula-
tion of the tissue-speciﬁc expression of the receptor since the
mouse NPFF2 variants have distinct expression patterns.The mouse NPFF2 receptor expression pattern diﬀers from
that of rat and, thus, the NPFF system may have species-spe-
ciﬁc functions.Acknowledgments: This study was supported by the Academy of Fin-
land and the Finnish Graduate School for Neurosciences.
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Supplementary data associated with this article can be found,
in the online version, at doi:10.1016/j.febslet.2006.11.063.References
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